Cidara Therapeutics Inc (NASDAQ:CDTX) Acquisition by Merck & Co Inc

Group 1 - Cidara Therapeutics Inc (NASDAQ:CDTX) is focused on developing innovative therapies for serious diseases, with a current stock price of $217.71, reflecting a 105.41% increase following Merck's acquisition announcement [1][2][5] - RBC Capital has set a price target of $221.50 for CDTX, which aligns with Merck & Co Inc's acquisition offer valuing the company at $221.50 per share [1][5] - Merck's acquisition of Cidara is a significant cash deal valued at $9.2 billion, more than double Cidara's stock price prior to the announcement [2][5] Group 2 - Following the acquisition news, CDTX shares surged by 105%, reaching a high of $217, indicating strong market response [2][3] - CDTX has a market capitalization of approximately $5.52 billion, reflecting its increased valuation post-acquisition announcement [4] - The trading volume for CDTX today is 17.29 million shares, indicating high investor interest [4][5]